Rexulti

Discussion in 'Sunovion' started by anonymous, Oct 19, 2023 at 11:44 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    From the Otsuka message board

    In the September 20-26 2023 issue of The Epoch Times, in an article entitled “Who Regulates the Regulators?”. The article states, “Despite that the drug (brexpiprazole, Rexulti) was found to provide no clinical meaningful benefit in trials and to increase the risk of death significantly, the FDA has fast tracked the drug’s approval. It’s now the first licensed antipsychotic drug for treating anxiety in dementia suffers.”

    It goes on to say, “In three pre-approved trials, the death rate for users of the drug was four times higher than that for placebo. In terms of efficacy, the drug brought only a 5.3-point improvement on a 174-point scale. Seventeen points in the minimum improvement deemed to be clinically important. “ the small benefits do not outweigh serious safety concerns,” researcher, Nina Zeldes told the FDA’s advisory committee, according to the British Medical Journal. Like other antipsychotics, this drug can kill patients without providing a meaningful benefit.”

    We have been selling, promoting and deceiving doctors for years that this drug was “safe and effective” and all the while it’s actually dangerous! A DEATH RATE 4 TIMES HIGHER THAN PLACEBO!!! Do you really want to continue to sell this piece of crap as if it actually was helping people?? If an office ASKS for samples they will get it, but I will no longer actively sell this drug in any office anymore.
     

  2. anonymous

    anonymous Guest

    Time to leave copies of this article with our physicians and see market share grow.
     
  3. anonymous

    anonymous Guest

    are you lost in your trolls? This company no longer has psych reps.
     
  4. anonymous

    anonymous Guest

    ?